NVO
Citi pours a little cold water on Novo
Novo Nordisk’s GLP-1 empire just got a less-than-cheery note from Citi, which flagged a slowdown in prescriptions and kept its Sell rating in place. That matters because Novo’s whole story has been tied to the weight-loss and diabetes boom — and when prescription growth starts acting like it’s stuck in traffic, investors notice.
Why this matters
This isn’t about one bad day on the ticker screen. It’s about the market re-checking whether Novo can keep growing like a caffeine-fueled startup when it’s actually a giant pharma company with giant expectations.
A slowdown in prescriptions can mean a few things:
- demand is normalizing after the initial hype wave
- competition is biting harder
- coverage, pricing, or supply dynamics are getting messier
Any of those can make the math on future sales a little less dreamy.
Big picture
Citi’s call doesn’t change the fact that Novo is still one of the biggest names in the obesity-drug trade. But it does put a spotlight on the one thing markets hate most: growth that starts to look less inevitable. Big picture: when a stock is priced for nonstop expansion, even a hint of a slowdown can feel like someone hitting pause on the whole movie.